Compared with originator bevacizumab, the biosimilar version of bevacizumab had equal efficacy when used to treat metastatic colorectal cancer. CRC is among the most common cancers worldwide while ...

Bevacizumab, a humanised monoclonal antibody targeting vascular endothelial growth factor (VEGF), has become integral to the management of metastatic colorectal cancer (mCRC). By binding VEGF and ...

Tumor-Targeted IL-12 (PDS01ADC) With Hepatic Artery Infusion Pump Therapy for Colorectal Liver Metastases: Interim Analysis of a Nonrandomized Phase II Trial Patients with mCRC exposed to FTD-TPI + ...

Adding oxaliplatin to a chemotherapy regimen already used in combination with bevacizumab (Avastin) for the treatment of metastatic colorectal cancer has been shown to double the 5-year survival rate.

The addition of bevacizumab (Avastin) to chemotherapy for the treatment of metastatic colorectal cancer may not be cost-effective, according to a report from Gastroenterology & Endoscopy News.

A phase 2 study of intravenous pembrolizumab and intratumorally injected autologous dendritic cells (DCs) in refractory colorectal cancer (CRC). This is an ASCO Meeting Abstract from the 2025 ASCO ...

CHICAGO (Reuters) - Colorectal cancer patients treated with a follow-up round of Avastin fare better than those given chemotherapy alone after their disease has worsened, according to results of a ...

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer ...